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| Amidolytic activity assay
FVIIa, Gla-domainless FVIIa, FVIIa DVQ 
| Human material
Human 
| TGA and TEG
To prepare platelet-rich plasma (PRP), citrate-stabilized blood was centrifuged at 220 g for 20 minutes, after which the platelets were transferred to a new tube and counted (range, 197 000-332 000 μL −1 ). PRP was used without adjusting the platelet density. For some experiments, platelet-poor plasma (PPP) was prepared by centrifugation at 2500 g for 10 minutes, resulting in a residual platelet count <50 
Essentials
• Factor VIIa (FVIIa; NovoSeven ® ) is a bypassing agent for treatment of hemophilia with inhibitors.
• Clinically effective concentrations of NovoSeven ® result in a subnormal thrombin peak in vitro.
• FVIIa concentration needed for normal thrombin peak is largely independent of platelet binding.
• Cautious interpretation of drug effect based on thrombin peak in static assay is warranted. 
| Statistics
Mean values and standard deviations were calculated by the software Prism 7 (GraphPad Software, La Jolla, CA).
| RESULTS AND DISCUSSION
Our aim was to characterize the general TGA response to FVIIa in HA plasma, with emphasis on the generated thrombin peak, and compare with TEG findings. Moreover, FVIIa was compared to Gla-domainless FVIIa and to full-length and Gla-domainless forms of the enzymatically superactive variant FVIIa DVQ . TGA and TEG measurements were performed on identical samples, and parallel, directly comparable analyses were made feasible by spiking FVIIa derivatives into PRP and initiating the reactions with a common trigger (0.1 pmol L −1 TF).
FVIIa, Gla-domainless (GD-) FVIIa, FVIIa DVQ , and GD-FVIIa DVQ in TGA and TEG. The indicated parameters were measured using PRP from healthy donors (n = 4) following antibody-induced HA and triggering by TF (0.1 pmol L −1 ). Data are shown as mean ± SD. In HA PRP without added FVIIa, the thrombin peak was 1% to 4% of normal PRP, velocity index 0.5% to 1%, lag time 2.8-to 5.8-fold longer than in normal PRP, R time 3.0-to 5.8-fold longer (if clotting occurred, 2 of the HA PRP samples produced no fibrin clot), and angle 0% to 30%. FVIIa, factor VIIa; FVIIa DVQ , V158D/E296V/M298Q-FVIIa; HA, hemophilia A; PRP, platelet-rich plasma; TEG, thromboelastography; TF, tissue factor; TGA, thrombin generation assay. 
Amidolytic activity measurements assured that equal added concentrations of the various FVIIa forms indeed represented the same amounts of enzymatically active molecules using FVIIa as the comparator. In practice, the nominal concentrations of the stock solutions were slightly adjusted so that the specific activity of Gla-domainless FVIIa equaled that of FVIIa 12 and the same applied to Gla-domainless FVIIa DVQ vs. FVIIa DVQ . Furthermore, FVIIa DVQ was set to having 8-fold higher specific activity than FVIIa, as established previously. 8 After this calibration, the proteins were ready for use in TGA/TEG measurements.
Initially, we quantified the effects of adding 25 nmol L −1 FVIIa derivative to HA PRP. Without added FVIIa, the thrombin peak was 1% to 4% of that in the corresponding control (non-HA) PRP. FVIIa induced the formation of a thrombin peak corresponding to 20% to 25% of that obtained in normal PRP (Figure 1 ). Gla-domainless FVIIa generated 8% to 10% of the normal thrombin peak, indicating that the presence of the Gla domain and the concomitant ability to associate with the platelet surface somewhat increased, but was not a prerequisite for, the thrombin-generating potential. Full-length and Gla-domainless FVIIa DVQ -induced thrombin peaks were around 100% and FVIIa apparently did not need to be platelet bound because it could largely be provided by FVIIa DVQ lacking the Gla domain ( Figure 1 ).
To substantiate this hypothesis further, increasing concentrations of Gla-domainless FVIIa were added to HA PRP and a similar, parallel improvement of the thrombin peak reaching 60-70% of that of normal, plasma at 900 nmol L −1 was observed (FVIIa: 80%-90%; Figure 2 ). The major part of the FVIIa effect thus appeared to be attributable to the sheer presence of large amounts of FVIIa enzymatic activity rather than to increased activity localization to the platelet surface.
To examine whether platelet activation was somehow responsible for FVIIa or Gla-domainless FVIIa present, lag and R times were already short and insensitive to changes in TF level.
FVIIa interacts with EPCR through the Gla domain, 14, 15 and activated human platelets recently have been shown to express EPCR. 16 In our study, a blocking anti-EPCR antibody did not influence the TGA/ TEG parameters, including the thrombin peak, after spiking FVIIa derivatives into HA PRP. This is in some disagreement with the findings of Fager et al, 16 who claimed a modest decrease of thrombin generation upon EPCR blockage. This might be explained by different modes of platelet activation and/or plasma environment (containing factor V and protein C) vs. a purified system (lacking protein C). Conceivably, the reason for the lacking effect of EPCR blockage in PRP is that a reduced formation of activated protein C balances a decreased FVIIa localization.
Our compiled data strongly suggest that the thrombin peak measured using TGA after adding FVIIa to HA PRP is governed by FVIIa enzymatic with NovoSeven ® does not produce a thrombin peak even closely resembling that seen in normal plasma. 13 Other TGA (and TEG) parameters are (almost) normalized and apparently more closely related to the clinical efficacy. However, thrombin peak normalization is feasible with FVIIa but requires 20 to 50 times higher levels (or a superactive variant). A limited impact of platelet surface binding on the FVIIa-induced thrombin peak is supported by data with Gla-domainless FVIIa and FVIIa DVQ and is presumably an assay artifact owing to the static, contained conditions. In a voluminous flowing system, such as under in vivo conditions, the situation is quite different. Gla-domainless FVIIa would not stop a bleed because it, unlike FVIIa, fails to localize to the site of injury. Accordingly, if TGA were used to screen for hemostatic drugs based on their induced thrombin peak, false-positive compounds lacking platelet surface binding ability would be anticipated owing to confinement of the reaction cascade leading to thrombin generation to the assay well. Finally, FVIIa mode of action studies using TGA should be performed with caution; in sharp contrast to our TGA finding, the relatively poor factor X-activating ability of FVIIa in solution leaves little doubt in our minds that phospholipid association is utterly important for the pharmacologic effect of FVIIa, 17 and neither does the documented effect of FVIIa on platelet adhesion and activation under flow conditions. 18 Recent data strongly supporting a TFindependent mode of action of FVIIa, neither competing with zymogen for TF nor requiring TF for its own effect, support the necessity of a direct interaction with procoagulant membrane surfaces.
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